Saga Investments LLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Saga Investments LLC
The blockbuster drug is expected to see overall sales declines in the next few years, and biosimilar competition could come as soon as 2023.
Private Company Edition: Clover’s $230m financing was the largest of recent mega-rounds. Century Therapeutics ($160m), Vividion ($135m) and eGenesis ($125m) also raised big rounds and investors Foresite Capital ($969m), Sofinnova Partners ($540m) and OMX Ventures ($150m) raised new VC funds.
ResMed beat Wall Street analysts’ projections for sales growth for the second quarter of 2021, announced exit of its portable oxygen market.
EY’s M&A Firepower report predicts very active M&A activity for medtechs in 2021, driven by diagnostics and digital health, but with some headwinds remaining.
- Other Names / Subsidiaries
- deCODE genetics ehf